Biolife Solutions INC

BioLife Solutions announces its merger with Repligen Corporation, aiming to accelerate growth and enhance bioprocessing capabilities.

Repligen Corporation announced its definitive agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion, aiming to expand its cell therapy capabilities.

BioLife Solutions presented an investor deck on June 3, 2026, detailing its industry-leading position in biopreservation and cell processing tools for cell-based therapies, showcasing strong revenue growth and strategic portfolio optimization.

BioLife Solutions, a leading provider of biopreservation and cell processing tools, issued an investor presentation detailing its strategic refocus, strong financial performance in 2025, and positive outlook for 2026.

BioLife Solutions announced robust fourth quarter and full year 2025 financial results, driven by its focused cell processing strategy, and provided optimistic 2026 guidance.

BioLife Solutions announced preliminary unaudited Q4 and full-year 2025 revenue from continuing operations, exceeding its raised guidance and signaling future growth.

BioLife Solutions posted a 31% revenue increase in Q3 2025, returning to net income while strategically divesting non-core assets and acquiring new cryopreservation technology.

BioLife Solutions reported a 29% revenue increase in Q2 2025, driven by strong cell processing and thawing product demand, alongside a widened net loss due to a $15.5 million R&D expense from the PanTHERA acquisition.

BioLife Solutions saw a 30% increase in revenue in Q1 2025, primarily driven by higher demand for its cell processing products.

BioLife Solutions reports a 30% increase in total revenue for the third quarter of 2024 compared to the same period last year, driven by strong growth in cell processing product sales.

BioLife Solutions' Q2 2024 results show a decrease in revenue and a net loss, impacted by customer destocking and the divestiture of Global Cooling.

BioLife Solutions experienced a decrease in revenue for the first quarter of 2024, alongside the strategic divestiture of its Global Cooling subsidiary.

BioLife Solutions files an amendment to its 2025 Annual Report to provide updated disclosures regarding corporate governance, executive compensation, and director information.

BioLife Solutions, Inc. reported a 29% increase in total revenue for 2025, driven by strong demand for biopreservation media products, while continuing to streamline its portfolio through strategic divestitures and acquisitions.

BioLife Solutions has filed an amendment to its 2024 Annual Report to restate Part III, covering directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, director independence, and principal accounting fees, and to file new certifications.

BioLife Solutions' 2024 10-K filing details financial performance, strategic shifts, and risk factors, highlighting a focus on bioproduction products and services after divesting other business segments.

BioLife Solutions' 10-K filing outlines the company's share structure, voting rights, dividend policies, and anti-takeover measures, along with details on its business operations and risk factors.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for a combination of cash and Repligen common stock, aiming to accelerate growth in the cell therapy market.

Sean Werner, Chief Technology Officer of Biolife Solutions Inc, reported a transaction in 275 shares of common stock on July 17, 2026.

Troy Wichterman, Chief Financial Officer of Biolife Solutions Inc, reported a transaction in 844 shares of common stock on July 7, 2026.

Aby J. Mathew, EVP & Chief Scientific Officer of Biolife Solutions Inc, reported a transaction in 516 shares of common stock on July 7, 2026.

Todd Berard, Chief Marketing Officer of Biolife Solutions Inc, reported a transaction in 293 shares of common stock on July 7, 2026.

CFO Troy Wichterman disposed of 1,026 shares of BioLife Solutions common stock to satisfy tax obligations related to restricted stock units.

BioLife Solutions, Inc. has filed its definitive proxy statement, Schedule 14A, with the U.S. Securities and Exchange Commission.

BioLife Solutions, Inc. announced robust 2024 financial results, including significant revenue growth and positive adjusted EBITDA, driven by strategic divestitures and a sharpened focus on the cell and gene therapy market, while also detailing executive compensation and corporate governance updates ahead of its 2025 Annual Meeting.

BioLife Solutions is actively addressing material weaknesses identified in its FY23 SOX compliance program, focusing on system implementation, internal controls, and resource expertise.

BioLife Solutions will hold its 2024 Annual Meeting of Stockholders virtually on August 1, 2024, to vote on director elections, executive compensation, and auditor ratification.

Casdin Capital, LLC has disclosed an increased beneficial ownership of 9.7% in BioLife Solutions, Inc. following recent share acquisitions.

Casdin Capital and its affiliates have increased their beneficial ownership in BioLife Solutions, Inc. to 12.4% through a recent share acquisition.

Casdin Capital and its affiliates have increased their beneficial ownership in BioLife Solutions, Inc. to 14.0% through a recent acquisition of 500,000 shares.

Casdin Capital, a key investor, has increased its beneficial ownership in BioLife Solutions, Inc. to 15.0% through a recent share acquisition.

Casdin Capital and its affiliates have increased their beneficial ownership in BioLife Solutions, Inc. to 16.2% of outstanding common stock, acquiring an additional 1,000,000 shares, and reserve the right to engage in actions aimed at maximizing shareholder value.

Casdin Capital, LLC and its affiliates have increased their beneficial ownership in BioLife Solutions, Inc. to 18.5% of outstanding common stock, primarily through shares received in BioLife's acquisition of PanThera CryoSolutions, Inc.

Casdin Capital, LLC and affiliated entities have reported a 9.7% beneficial ownership stake in BioLife Solutions, Inc. as of June 4, 2026.

Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of BioLife Solutions Inc. common stock as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in BioLife Solutions Inc. common stock following an internal realignment.

Invesco Ltd. has reported an 8.2% beneficial ownership stake in BioLife Solutions Inc. common stock as of December 31, 2025.

T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 10.8% in BioLife Solutions Inc. common stock.

T. Rowe Price Investment Management, Inc. reported beneficial ownership of 8.9% of BioLife Solutions Inc. common stock, totaling 4,246,706 shares.